Affiliation:
1. Division of Cardiology Department of Medicine University of Alberta Edmonton Canada
2. Mazankowski Alberta Heart Institute University of Alberta Edmonton Canada
3. Division of Medical Genetics Department of Pediatrics Université de Sherbrooke Québec Canada
4. Department of Medical Genetics University of Alberta Edmonton Canada
5. Department of Medical Genetics and Pediatrics University of Calgary Canada
6. Division of Nephrology Department of Medicine Dalhousie University Halifax Canada
Abstract
Background
Because systemic inflammation and endothelial dysfunction lead to heart failure with preserved ejection fraction, we characterized plasma levels of inflammatory and cardiac remodeling biomarkers in patients with Fabry disease (
FD
).
Methods and Results
Plasma biomarkers were studied in multicenter cohorts of patients with
FD
(n=68) and healthy controls (n=40). Plasma levels of the following markers of inflammation and cardiac remodeling were determined: tumor necrosis factor (
TNF
),
TNF
receptor 1 (
TNFR
1) and 2 (
TNFR
2), interleukin‐6, matrix metalloprotease‐2 (
MMP
‐2),
MMP
‐8,
MMP
‐9, galectin‐1, galectin‐3, B‐type natriuretic peptide (
BNP
), midregional pro–atrial natriuretic peptide (
MR
‐pro
ANP
), and globotriaosylsphingosine. Clinical profile, cardiac magnetic resonance imaging, and echocardiogram were reviewed and correlated with biomarkers. Patients with
FD
had elevated plasma levels of
BNP
,
MR
‐pro
ANP
,
MMP
‐2,
MMP
‐9,
TNF
,
TNFR
1,
TNFR
2, interleukin‐6, galectin‐1, globotriaosylsphingosine, and analogues. Plasma
TNFR
2,
TNF
, interleukin‐6,
MMP
‐2, and globotriaosylsphingosine were elevated in
FD
patients with left ventricular hypertrophy, whereas diastolic dysfunction correlated with higher
BNP
,
MR
‐pro
ANP
, and
MMP
‐2 levels. Patients with late gadolinium enhancement on cardiac magnetic resonance imaging had greater levels of
BNP
,
MR
‐pro
ANP
,
TNFR
1,
TNFR
2, and
MMP
‐2. Plasma
BNP
,
MR
‐pro
ANP
,
MMP
‐2,
MMP
‐8,
TNF
,
TNFR
1,
TNFR
2, galectin‐1, and galectin‐3 were elevated in patients with renal dysfunction. Patients undergoing enzyme replacement therapy who have more severe disease had higher
MMP
‐2,
TNF
,
TNFR
1,
TNFR
2, and globotriaosylsphingosine analogue levels.
Conclusions
Inflammatory and cardiac remodeling biomarkers are elevated in
FD
patients and correlate with disease progression. These features are consistent with a phenotype dominated by heart failure with preserved ejection fraction and suggest a key pathogenic role of systemic inflammation in
FD
.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine